These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. CRISPR-Cas9 interrogation of a putative fetal globin repressor in human erythroid cells. Chung JE; Magis W; Vu J; Heo SJ; Wartiovaara K; Walters MC; Kurita R; Nakamura Y; Boffelli D; Martin DIK; Corn JE; DeWitt MA PLoS One; 2019; 14(1):e0208237. PubMed ID: 30645582 [TBL] [Abstract][Full Text] [Related]
29. Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies. Paschoudi K; Yannaki E; Psatha N Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298481 [TBL] [Abstract][Full Text] [Related]
30. Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates. Romero Z; Lomova A; Said S; Miggelbrink A; Kuo CY; Campo-Fernandez B; Hoban MD; Masiuk KE; Clark DN; Long J; Sanchez JM; Velez M; Miyahira E; Zhang R; Brown D; Wang X; Kurmangaliyev YZ; Hollis RP; Kohn DB Mol Ther; 2019 Aug; 27(8):1389-1406. PubMed ID: 31178391 [TBL] [Abstract][Full Text] [Related]
31. Base editing of key residues in the BCL11A-XL-specific zinc finger domains derepresses fetal globin expression. Rajendiran V; Devaraju N; Haddad M; Ravi NS; Panigrahi L; Paul J; Gopalakrishnan C; Wyman S; Ariudainambi K; Mahalingam G; Periyasami Y; Prasad K; George A; Sukumaran D; Gopinathan S; Pai AA; Nakamura Y; Balasubramanian P; Ramalingam R; Thangavel S; Velayudhan SR; Corn JE; Mackay JP; Marepally S; Srivastava A; Crossley M; Mohankumar KM Mol Ther; 2024 Mar; 32(3):663-677. PubMed ID: 38273654 [TBL] [Abstract][Full Text] [Related]
32. Ex vivo culture resting time impacts transplantation outcomes of genome-edited human hematopoietic stem and progenitor cells in xenograft mouse models. Demirci S; Khan MBN; Hinojosa G; Le A; Leonard A; Essawi K; Gudmundsdottir B; Liu X; Zeng J; Inam Z; Chu R; Uchida N; Araki D; London E; Butt H; Maitland SA; Bauer DE; Wolfe SA; Larochelle A; Tisdale JF Cytotherapy; 2024 Jun; 26(6):641-648. PubMed ID: 38506770 [TBL] [Abstract][Full Text] [Related]
33. CRISPR-Cas9 Editing of the Sharma A; Boelens JJ; Cancio M; Hankins JS; Bhad P; Azizy M; Lewandowski A; Zhao X; Chitnis S; Peddinti R; Zheng Y; Kapoor N; Ciceri F; Maclachlan T; Yang Y; Liu Y; Yuan J; Naumann U; Yu VWC; Stevenson SC; De Vita S; LaBelle JL N Engl J Med; 2023 Aug; 389(9):820-832. PubMed ID: 37646679 [TBL] [Abstract][Full Text] [Related]
34. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells. DeWitt MA; Magis W; Bray NL; Wang T; Berman JR; Urbinati F; Heo SJ; Mitros T; Muñoz DP; Boffelli D; Kohn DB; Walters MC; Carroll D; Martin DI; Corn JE Sci Transl Med; 2016 Oct; 8(360):360ra134. PubMed ID: 27733558 [TBL] [Abstract][Full Text] [Related]
35. Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins. Pavani G; Laurent M; Fabiano A; Cantelli E; Sakkal A; Corre G; Lenting PJ; Concordet JP; Toueille M; Miccio A; Amendola M Nat Commun; 2020 Jul; 11(1):3778. PubMed ID: 32728076 [TBL] [Abstract][Full Text] [Related]
36. Base editing of the HBG promoter induces potent fetal hemoglobin expression with no detectable off-target mutations in human HSCs. Han W; Qiu HY; Sun S; Fu ZC; Wang GQ; Qian X; Wang L; Zhai X; Wei J; Wang Y; Guo YL; Cao GH; Ji RJ; Zhang YZ; Ma H; Wang H; Zhao M; Wu J; Bi L; Chen QB; Li Z; Yu L; Mou X; Yin H; Yang L; Chen J; Yang B; Zhang Y Cell Stem Cell; 2023 Dec; 30(12):1624-1639.e8. PubMed ID: 37989316 [TBL] [Abstract][Full Text] [Related]
37. Lentiviral Transfer of γ-Globin with Fusion Gene NUP98-HOXA10HD Expands Hematopoietic Stem Cells and Ameliorates Murine β-Thalassemia. Zhao HF; Abraham A; Kim YS; Wang YD; Pestina T; Zhan J; Humphries K; Nienhuis AW; Persons DA Mol Ther; 2017 Mar; 25(3):593-605. PubMed ID: 28190779 [TBL] [Abstract][Full Text] [Related]
38. Preclinical evaluation for engraftment of CD34 Uchida N; Li L; Nassehi T; Drysdale CM; Yapundich M; Gamer J; Haro-Mora JJ; Demirci S; Leonard A; Bonifacino AC; Krouse AE; Linde NS; Allen C; Peshwa MV; De Ravin SS; Donahue RE; Malech HL; Tisdale JF Cell Rep Med; 2021 Apr; 2(4):100247. PubMed ID: 33948577 [TBL] [Abstract][Full Text] [Related]
39. Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene. Zhao H; Pestina TI; Nasimuzzaman M; Mehta P; Hargrove PW; Persons DA Blood; 2009 Jun; 113(23):5747-56. PubMed ID: 19365082 [TBL] [Abstract][Full Text] [Related]
40. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia. Ye L; Wang J; Tan Y; Beyer AI; Xie F; Muench MO; Kan YW Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10661-5. PubMed ID: 27601644 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]